{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Other"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001007563"],"host":["EGA"],"description":["EGA study EGAS00001007563"],"dataset_title":["neoALTTO"],"repository":["EGA"],"category":["restricted"],"description_synonyms":["Erbb-2, 6beta, Neoadjuvant Chemoradiation Treatment, Receptors, Lactiferous gland, Tumor, GW282974X, Neoadjuvant Radiation Treatment, Kiaa3023, Systemic Therapy, responsivity, BCR, Antigen, CG40494, 3, cancer of the breast, 4, 5, GW572016, 6, Polymerase Chain, 8, 9, treatment, BC, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine, 4abeta, endocrine, AI853148, cancer of breast, scientific observation, Homo sapiens disease, Lymphoid, Breast Malignant Neoplasms, Tumors, Anchored Polymerase Chain Reaction, Radiation, GW-572016, T-Cell Receptor, T-Cell Antigen, (2aR-(2aalpha, Herceptin, e(Pc), MLN19, Receptor Agonists, 12balpha))-, GW 282974X, predicted, DmIKKgamma, Antigen Receptor, Benign, T Cell Receptor, dIKK, Radiotherapy, Lapatinib Ditosylate, Lobe of mammary gland, Chemotherapy, Lymphoid Cell, Neoadjuvant Radiation Treatments, 7-epi-Taxol, SIN, Neoadjuvant Chemoradiations, c-neu, 5beta, AI561783, PCR, Carcinomas, DmelCG7776, death rate, HTX5, IKK-gamma, Benign Neoplasms, 9alpha(alpha R*, \"mammary neoplasm\" RELATED [], Neoadjuvant Chemotherapies, SmokTcr, 12aalpha, NSC-125973, polymerase chain reaction, Malignant Neoplasms, (4 alpha)-Isomer, 1-2alpha, Paxene, breast cancer, DmelLcp3, Neoadjuvant Chemoradiation Treatments, Breast Tumors, BG:DS02740.11, Cells, Breast Malignant Tumors, Dominant negative form of Smok, T Cell, other neoplasm, cancer, GH05739, Neoplasms, N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE, 5133400C09Rik, Mammary Cancers, Polymerase Chain Reactions, Neoadjuvant Chemoradiotherapies, dIKK-gamma, Neoadjuvant Therapies, Human, Hormone, CML, Breast Malignant Tumor, GH14582, Breast Tumor, DmIKK-gamma, Girls, 12alpha, disease or disorder, breast tumor, nodal4-A, HER-2/neu, Benzenepropanoic acid, DmelCG40494, DmelCG2043, lcp3, Neoadjuvant Radiations, Mammary Neoplasm, Mammary Carcinoma, LCP-3, 13alpha-hexahydroxytax-11-en-9-one 4, PHL, Neoplasias, GW 572016, CP3, Neoadjuvant Chemoradiotherapy, Malignant Tumor of Breast, Anchored PCR, Neoadjuvant Systemic Treatment, Onxol, beta-(benzoylamino)-alpha-hydroxy-, Neu, NEU, Cancer, ALL, measuring, Breast Carcinoma, Human Mammary Neoplasm, Bris, Breast Carcinomas, LcpIII, Malignant Neoplasm, Women's Group, HER-2|neu, Women Groups, disorders, 7beta, \"breast tumor\" EXACT [NCI2004_11_17:C2910], Cell, Neoadjuvant Systemic Treatments, IKKgamma, Tg.413d, TCR complex, Neoplasm, NGL, Human Mammary Carcinoma, condition, supply and distribution, LCP3, Lymphoid Cells, T lymphocyte receptor complex, nodal4, DMLCP3, c-erbB2, Dmikkgamma, l(2)28-28-12, Lobe of breast, Cancers, 7 epi Taxol, CG16910, beta, DmelCG5861, Trastuzumab-qyyp, Neoadjuvant Chemotherapy Treatment, T Cell Receptors, Radiation Therapy, T-Cell Antigen Receptors, Cancer of Breast, Receptor, CG2043, Neoadjuvant Systemic Therapies, Neoadjuvant Chemoradiation Therapies, Neoplasia, breast, malignant tumor of the breast, 11alpha, Breasts, Feature, supply, mammary neoplasm, Human Mammary Neoplasms, TAXOL, Neoadjuvant Treatment, glandula mammaria, 10, 11, Neoadjuvant Treatments, CD340, 12, 13, Neoadjuvant Systemic Therapy, diseases, \"neoplasm of breast (disorder)\" EXACT [SNOMEDCT_2005_07_31:126926005], 10-diacetate 2-benzoate 13-ester with (2R, diseases and disorders, IKKg, KEY, Key, BCR1, Mammary Neoplasms, malignant neoplasm of breast, 12b-dodecahydro-4, Immune Processes, Immune Responses, Trastuzumab beta, human disease, Hormone Receptor, T Cell Antigen Receptor, Human Mammary Carcinomas, Inverse Polymerase Chain Reaction, Paclitaxel, Systemic Treatment, free, 12a, Taxol, Immune, Neoadjuvant Chemotherapy, Reaction, disease management, Therapies, CG7776, Malignancies, mammary cancer, NODAL, Neoadjuvant Radiotherapy, EFS2, mamma, Therapy, Carcinoma, GW-282974X, \"breast neoplasm\" EXACT [MTH:120], Process, Chemoradiation, Trazimera, L[[3]]CP3, Girl, D22S662, T-Cell, Neoadjuvant Chemoradiation, HEFS, 4a, Kenny, Diseases, NOS, Praxel, Malignant Neoplasm of Breast, EFS1, Neoadjuvant, Nested Polymerase Chain Reaction, Chemotherapy Treatment, 4)benz(1, Features, Treatments, CG17960, NSC 125973, 10beta, MLN 19, disease, DmelCG16910, Neoadjuvant Chemoradiation Therapy, Patient, E(PC), anon-48Ac, TKR1, nr4, medical condition., T-cell receptor complex, Dmel_CG00000, CAS3, mammary region, Neoadjuvant Radiation Therapies, primary breast cancer, other disease, Neoadjuvant Radiation Therapy, Neoadjuvant Radiotherapies, Chemoradiotherapy, infiltrating, Benign Neoplasm, Inverse, Neoadjuvant Systemic, Malignant, Tykerb, 12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6, Responder protein Smok-Tcr, Inverse PCR, CG17617, 12b-bis(acetyloxy)-12-(benzoyloxy)-2a, III, RRG6, Taxol A, NSC125973, 4beta, \"mammary tumor\" EXACT [CSP2005:2016-0671], rhoGAP1A, dmIKKgamma, IKK[[gamma]], Agonists, Bris Taxol, xnr4, reactivity, Human Mammary, hormones, Chemoradiation Therapy, 11-dihydroxy-4a, 2-alpha, Malignancy, distribution, HER-2, D22S11, 9alpha(alphaR*, mammary part of chest, 2-b)oxet-9-yl ester, Hormone Receptor Agonists, EG:23E12.5, EG:23E12.2, Cancer of the Breast, T-Cell Receptors, non-neoplastic, 11-methano-1H-cyclodeca(3, GEP6, Immune Response, IKK, time of survival, Clients, Mammary, Mammary Cancer, Chemoradiation Treatment, disorder, Characteristics, Breast, N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine, Immune Process, mammary tumor, CASS3, Antigen Receptors, Lymphocyte, T-Cell Antigen Receptor, T-lymphocyte receptor complex, Trastuzumab qyyp, mKIAA3023, 20-Epoxy-1, Brustdruese, Client, Woman, 3S)-N-benzoyl-3-phenylisoserine, Breast Malignant Neoplasm, T Cell Antigen, 13-tetramethyl-5-oxo-7, 2.7.11.1, Characteristic, survival, Mammary Carcinomas, CG40453, Trastuzumab, TCR, Tcr, Anchored, Breast Neoplasm, Reactions, Nested, Women's Groups, anon-35Fa, Neoadjuvant Radiation, Neoadjuvant Chemotherapy Treatments, Radiation Treatment, Therapeutic, anon-35Fc, Breast Cancer, betaS*), Response, Nested PCR, Treatment, response, mKIAA3017, Anzatax, HER2"],"name_synonyms":["Erbb-2, Breast Carcinoma, Human Mammary Neoplasm, primary breast cancer, Carcinoma, malignant tumor of the breast, Breast Carcinomas, \"breast neoplasm\" EXACT [MTH:120], Feature, Neoplasms, HER-2|neu, mKIAA3023, mammary neoplasm, Mammary Cancers, Human Mammary Neoplasms, Prognostic Factors, MLN19, Factor, Tumor, \"breast tumor\" EXACT [NCI2004_11_17:C2910], Human, CD340, Breast Malignant Neoplasm, Breast Malignant Tumor, Characteristic, Kiaa3023, RRG6, \"neoplasm of breast (disorder)\" EXACT [SNOMEDCT_2005_07_31:126926005], Mammary Carcinomas, Breast Tumor, Neoplasm, NGL, Human Mammary Carcinoma, \"mammary tumor\" EXACT [CSP2005:2016-0671], NOS, breast tumor, cancer of the breast, HER-2/neu, Malignant Neoplasm of Breast, c-neu, Carcinomas, BC, Mammary Neoplasms, malignant neoplasm of breast, Human Mammary, Breast Neoplasm, Prognoses, Factors, c-erbB2, Mammary Neoplasm, HER-2, Prognostic, Mammary Carcinoma, Human Mammary Carcinomas, Cancers, \"mammary neoplasm\" RELATED [], Prognostic Factor., Features, Cancer of the Breast, MLN 19, GEP6, breast cancer, cancer of breast, Malignant Tumor of Breast, Mammary, Mammary Cancer, Breast Tumors, Breast Cancer, Breast Malignant Tumors, TKR1, Cancer of Breast, Characteristics, Breast, mammary cancer, cancer, mammary tumor, Breast Malignant Neoplasms, HER2, breast, Neu, NEU, Tumors, Cancer"],"additional_accession":[]},"is_claimable":false,"name":"Immune and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 trials","description":"The identification of prognostic drivers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigated the complexity of B and T cell receptor (BCR and TCR) repertoires, reflecting antigen-specific immune response, in the context of two phase III trials, namely NeoALTTO and CALGB 40601, evaluating neoadjuvant paclitaxel with trastuzumab and/or lapatinib in women affected by HER2-positive breast cancer. BCR/TCR features were heterogeneous, and BCR measures describing clonal expansion demonstrated independent prognostic value. A model developed in NeoALTTO and validated in CALGB 40601 predicted event-free survival (EFS) by integrating hormone receptor and clinical nodal status, treatment response (breast pCR)breast pathological complete response (pCR) as well as tumor-infiltrating lymphocytes and BCR evenness, measuring the equality of BCR clonal distribution. The HER2-EveNT score derived from the model allows the identification of patients with 5-year EFS > 90%, and, in those not achieving pCR, of a subgroup of immune-enriched tumors with an excellent outcome despite residual disease.","dates":{"updated":"2023-09-20 15:14:10"},"accession":"EGAS00001007563","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001011354","EGAC00001003428"]}}